Benitec Biopharma (BNTC) Common Equity (2019 - 2025)

Benitec Biopharma has disclosed Common Equity across 7 years of filings, most recently posting $187.4 million for Q4 2025.

• Common Equity for Q4 2025 came in at $187.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $187.4 million (changed N/A YoY), and the FY2025 annual result was $97.3 million, up 105.92% from the prior year.
• Common Equity came in at $187.4 million for Q4 2025 at Benitec Biopharma, up from $93.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $187.4 million in Q4 2025 to a low of -$219.4 million in Q1 2025.
• The 5-year median for Common Equity is $11.5 million (2024), against an average of $18.5 million.
• Across the five-year window, Common Equity surged 23290.1% in 2024 and sank 2007.57% in 2025, its largest moves.
• Benitec Biopharma's Common Equity stood at $10.8 million in 2021, then retreated by 17.0% to $9.0 million in 2022, then surged by 72.0% to $15.5 million in 2023, then sank by 106.42% to -$993000.0 in 2024, then jumped by 18968.18% to $187.4 million in 2025.
• The last three Common Equity figures came in at $187.4 million (Q4 2025), $93.6 million (Q3 2025), and $97.3 million (Q2 2025), per Business Quant data.